Rhythm Pharmaceuticals, Inc. has announced a public offering of $150 million in common stock. All securities in this offering will be offered by Rhythm, and the company plans to grant underwriters a 30-day option to purchase an additional $22.5 million in shares. The offering is being conducted under a shelf registration statement on Form S-3, which became effective in March 2023. The offering's final terms, including size and conditions, will be disclosed in a prospectus supplement filed with the SEC. Morgan Stanley, BofA Securities, Stifel, and Wells Fargo Securities are serving as joint book-running managers, while Canaccord Genuity and Citizens Capital Markets are acting as lead managers. Completion of the offering is subject to market conditions and other customary closing conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.